NCT07272343

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Second Affiliated Hospital of Nanchang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.

Conditions

• Type 2 Diabetes Mellitus (T2DM)
• Semaglutide
• Caloric Restriction

Interventions

Type	Name	Description
DRUG	semaglutide	The semaglutide group received weekly subcutaneous semaglutide (0.25 mg for weeks 1-2, 0.5 mg for weeks 3-4, and 1.0 mg for weeks 5-12).
BEHAVIORAL	caloric restriction	The caloric restriction group followed a gender-specific daily caloric restriction (1,500-1,800 kcal for males; 1,200-1,500 kcal for females).

Timeline

• Start date: 2023-02-10
• Primary completion: 2026-06-30
• Completion: 2026-07-01
• First posted: 2025-12-09
• Last updated: 2026-04-02

Locations

1 site across 1 country: China